Glycemic variability in newly diagnosed diabetic cats treated with the glucagon‐like peptide‐1 analogue exenatide extended release

BACKGROUND: Glycemic variability (GV) is an indicator of glycemic control and can be evaluated by calculating the SD of blood glucose measurements. In humans with diabetes mellitus (DM), adding a glucagon‐like peptide‐1 (GLP‐1) analogue to conventional therapy reduces GV. In diabetic cats, the influ...

Descripción completa

Detalles Bibliográficos
Autores principales: Krämer, Anna L., Riederer, Angelina, Fracassi, Federico, Boretti, Felicitas S., Sieber‐Ruckstuhl, Nadja S., Lutz, Thomas A., Contiero, Barbara, Zini, Eric, Reusch, Claudia E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
SMALL ANIMAL
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694851/
https://www.ncbi.nlm.nih.gov/pubmed/33001499
http://dx.doi.org/10.1111/jvim.15915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694851/
https://www.ncbi.nlm.nih.gov/pubmed/33001499
http://dx.doi.org/10.1111/jvim.15915

Ejemplares similares